CTLA4 and lung carcinoma: In this context, PD-L1 and Cytotoxic T-lymphocyte protein 4 (CTLA-4) pathways, which are significantly involved in tumor-induced immune control, are now druggable and still under evaluation to elucidate gender differences also in lung cancer.